- Home
- MTR vs XAIR Comparison
MTR vs XAIR Comparison
Compare MTR & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MTR | XAIR |
|---|---|---|
| Founded | 1979 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8M | 5.4M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | MTR | XAIR |
|---|---|---|
| Price | $3.15 | $0.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 8.4K | ★ 240.3K |
| Earning Date | 03-31-2026 | 06-16-2026 |
| Dividend Yield | ★ 4.82% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,679,000.00 |
| Revenue This Year | N/A | $122.00 |
| Revenue Next Year | N/A | $58.15 |
| P/E Ratio | $22.60 | ★ N/A |
| Revenue Growth | N/A | ★ 107.26 |
| 52 Week Low | $3.06 | $0.33 |
| 52 Week High | $5.98 | $3.78 |
Technical Indicators
Market Signals| Indicator | MTR | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 32.91 | 40.48 |
| Support Level | N/A | $0.36 |
| Resistance Level | $4.89 | $0.52 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 26.47 | 23.48 |
Price Performance
Historical ComparisonAbout MTR Mesa Royalty Trust
Mesa Royalty Trust holds net overriding royalty interests in various oil and gas properties located in the: Hugoton field of Kansas, San Juan Basin field of New Mexico, and San Juan Basin Field of Colorado.
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.